Skip to main content

Table 4 Comparison of the scores of PRO for migraine (FAS)

From: Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial

 

Treatment group (n = 177)

Control group (n = 180)

P values

Total score

 4w

29.68 ± 5.87

30.18 ± 5.86

0.767

 8w

26.97 ± 6.72

26.79 ± 7.26

0.455

 12 w

22.90 ± 6.63

23.80 ± 7.27

0.301

 Follow-up period

21.61 ± 6.47

23.41 ± 6.80

0.021*

Headache

 4w

10.88 ± 2.07

11.05 ± 2.24

0.725

 8w

9.56 ± 2.62

9.52 ± 2.76

0.643

 12 w

8.54 ± 2.78

8.23 ± 2.88

0.246

 Follow-up period

7.95 ± 2.73

8.31 ± 2.98

0.283

Somatization symptoms

 4w

9.46 ± 2.66

9.48 ± 2.48

0.022*

 8w

8.83 ± 2.67

8.57 ± 2.72

0.340

 12 w

7.62 ± 2.51

7.72 ± 2.65

0.660

 Follow-up period

7.52 ± 2.49

7.61 ± 2.38

0.745

Psychological state

 4w

4.26 ± 1.36

4.43 ± 1.45

0.650

 8w

3.97 ± 1.36

4.14 ± 1.56

0.565

 12w

3.51 ± 1.29

3.81 ± 1.39

0.086

 Follow-up period

3.42 ± 1.24

3.72 ± 1.29

0.101

Functional status

 4w

5.08 ± 1.41

5.22 ± 1.52

0.697

 8w

4.61 ± 1.58

4.55 ± 1.63

0.442

 12 w

3.23 ± 1.36

4.04 ± 1.59

P < 0.001*

 Follow-up period

2.71 ± 1.16

3.77 ± 1.46

P < 0.001*

  1. *P < 0.05 for data comparison between groups aftertreatment